HARROW, INC. (HROW)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 63,742 | 47,831 | 49,257 | 48,939 |
| Cost of sales | 16,230 | 15,524 | 12,018 | 12,539 |
| Gross profit | 47,512 | 32,307 | 37,239 | 36,400 |
| Selling, general and administrative | 33,235 | 40,513 | 33,645 | 31,817 |
| Research and development | 2,868 | 3,026 | 2,273 | 3,053 |
| Total operating expenses | 36,103 | 43,539 | 35,918 | 34,870 |
| Income (loss) from operations | 11,409 | -11,232 | 1,321 | 1,530 |
| Other (expense) income, net | -6 | - | 4 | 46 |
| Interest expense, net | 6,408 | 6,548 | 5,525 | 5,471 |
| Investment loss from eton pharmaceuticals | - | - | - | -1,923 |
| Total other expense, net | -6,414 | -6,548 | -5,521 | -7,348 |
| Income (loss) before income taxes | 4,995 | - | -4,200 | -5,818 |
| Income tax expense | - | - | 20 | 655 |
| Net income (loss) | 4,995 | -17,780 | -4,220 | -6,473 |
| Basic net income (loss) per share of common stock | 0.14 | -0.5 | -0.12 | -0.18 |
| Diluted net income (loss) per share of common stock | 0.13 | -0.5 | -0.12 | -0.18 |
| Weighted average number of shares of common stock outstanding, basic | 36,790,306 | 35,826,452 | 35,702,200 | 35,618,977 |
| Weighted average number of shares of common stock outstanding, diluted | 38,853,855 | 35,826,452 | 35,702,200 | 35,618,977 |